• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.10 no.1
• /
• pp.63-72
• /
• 2024

Recent advances in disease understanding have led to the discovery of new molecular targets and biomarkers. Therapeutic antibodies targeting specific molecules have been successful in the development of antibody-drug conjugates (ADCs) due to their proven clinical effectiveness and manageable toxicity. Antibody-radionuclide conjugates (ARCs), which use radionuclides instead of drugs, also show promise for their potential therapeutic effects in radioimmunotherapy. Identifying these biomarkers before treatment is increasingly important, leading to personalized medicine. Immuno-positron emission tomography (PET) using radiolabeled monoclonal antibodies is promising for non-invasively assessing target expression and distribution. It can provide valuable information for risk assessment, diagnosis, treatment selection, and evaluation of treatment response. This review discusses recent developments in ADC and ARC and aims to explore opportunities for the simultaneous progress of these drugs.